Therapeutic algorithms for Crohn’s disease: Where are we in 2012?

Slides:

Advertisements

Similar presentations

Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.

Advertisements

Methotrexate Indications and Approaches

Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.

Miguel Regueiro, M.D. Professor of Medicine

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.

Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:

Colitis in the Very Young

Management of Inflammatory bowel disease 8/12/10.

Thiopurines have no role in the management of Pediatric IBD Robert N. Baldassano, MD Colman Professor of Pediatrics University of Pennsylvania, Perelman.

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.

6-MP and AZA Applications and Approaches

Therapy of Inflammatory Bowel Diseases 2013 Gastroenterology Department Division of Medicine Eran Israeli MD.

State of the Art Management of Crohn’s Disease

When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Current and Evolving Therapy of Crohn’s Disease (CD) Orooj khan MBBS Ali Minhas MBBS Maya Srivastava MD PhD.

Biologics: Indications and Approaches Russell D. Cohen, MD, AGAF, FACG Professor of Medicine, Pritzker School of Medicine Director IBD Center Co-Director.

UC. Ulcerative Colitis ( UC ) Ulcerative colitis is an inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract It is.

Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.

Inflammatory Bowel Diseases Dr. Nematollah Ahangar Assistant Prof. of Pharmacology.

Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.

William J. Sandborn, MD Chief, Division of Gastroenterology

Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Prof. Hanan Hagar Pharmacology Department College of Medicine.

Evidence-Based Medicine Changing Practice Dr Feagan’s Top 10 Clinical Trials c/o Dr Brian Feagan Presented and updated by Barrett Levesque MD, Director,

“Antibiotics and corticosteroids: Indications and approaches”

How Should the Risk of Malignant and Infectious Complications Influence My Treatment Choice Meenakshi Bewtra, MD, MPH, PhD University of Pennsylvania Division.

NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.

Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.

1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P

The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.

Chronic inflammatory Bowel Diseases By Prof. Abdulqader Alhaider 1434H.

Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Profs. Alhaider and Hanan Hagar Pharmacology Department College of Medicine.

EFFICACY OF EARLY TREATMENT WITH INFLIXIMAB IN PEDIATRIC CROHN’S DISEASE Matthew Sampson.

IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.

Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.

You Can Never Stop a Biologic

Natalizumab- Unmet Need in the Management of Crohn’s Disease Doug Wolf, M.D. Atlanta Gastroenterology Associates July 31, 2007.

IBD Treatment: The Basics

Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.

Early Administration of Azathioprine Versus Conventional Management of Crohn’s Disease : A Randomized Controlled Trial F1. Ja Won Koo JACQUES COSNES, ANNE.

(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2015 Comparison of (Your site name) results against the national results.

Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,

GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis

R3. 최태웅 / Pf. 김효종 Alimentary Pharmacology & Therapeutics 19 FEB 2016 DOI: /apt.13547

Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University.

Dr Gill Watermeyer IBD Clinic Division of Gastroenterology

Rheumatoid Arthritis: Management and New Therapies

IBD Therapies: Guidance for Managed Care Professionals

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Changing the IBD Paradigm

Complicated Cases in Ulcerative Colitis

Optimizing Patient Outcomes in IBD

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Illustrations in Ulcerative Colitis

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Methotrexate for Ulcerative Colitis: To Use or Not to Use?

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

“Drugs used in IBD and biological and immune therapy of IBD ”

Pathogenesis of IBD, and the Role of Biologic Therapies

Prof. Hanan Hagar Pharmacology Unit College of Medicine

Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.

Presentation data from US VICTORY Consortium

Presentation data from US VICTORY Consortium

Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

Slides compiled by Dr. Najma Ahmed

Presentation transcript:

Therapeutic algorithms for Crohn’s disease: Where are we in 2012?

Classic management of CD is sequential

A competing treatment concept!

Most Crohn’s disease patients will require surgery

Mortality in Crohn’s disease

Case presentation: Active CD

Endoscopy shows both TI and cecal involvement

Endoscopic image showing deep ulcerations

National Cooperative Crohn's Disease Study (NCCDS): Induction of remission in Crohn's disease

Mesalamine (5-ASA): Induction of remission in Crohn's disease

5-ASA for induction of remission in Crohn's disease: A meta-analysis

Corticosteroids in IBD

Budesonide absorption and metabolism

Budesonide vs mesalamine: Induction of remission

Azathioprine (AZA) maintenance therapy after corticosteroid-induction in Crohn's disease

Combination induction therapy 6-mercaptopurine (6-MP) + prednisone

Rates of surgery for CD and the use of immunosuppressives over 3 decades

Methotrexate: Widely used to treat severe arthritis in the past

Methotrexate results: Remission

Results: Time to relapse

Anti-TNFα-inhibitors

Maintenance of remission in Crohn's disease

Adalimumab + methotrexate in early rheumatoid arthritis: PREMIER study

Remission rate at Week 52 in CHARM by immunosuppressive use

Azathioprine monotherapy vs infliximab + azathioprine in steroid-dependent CD

Early combination therapy vs conventional management of Crohn’s disease

Use of drug with conventional or early aggressive therapy

Early aggressive therapy vs conventional management of Crohn’s disease

Early combination therapy vs conventional management of Crohn’s disease: Complete disappearance of ulceration

SONIC: Clinical remission without corticosteroids at Week 26

Optimum efficacy by treatment of patients with objective measures of inflammation

Schematic overview of COMMITT trial design

COMMITT: Proportion of patients with treatment success

OK, so we just treat everyone with combination therapy forever!!??

Predictors of rapid progression to surgery

Prognosis of CD patients with severe colonic ulceration

Positive serology and risk of progression

High risk patients should be considered for early treatment with combined therapy

Back to our CD case

Kaplan-Meier CD-related hospitalization: CHARM

Safety data from the TREAT registry

Lymphoma risk and IBD  Lymphoma risk is well established  Special case of HTCL  Non-melanoma skin cancer similarly elevated  Highly concerning to patients

Methotrexate and lymphoma risk “The hypothesis that disease-modifying drugs, and in particular methotrexate, would increase the lymphoma risk receives little support.” Baecklund et al, Current Opinion Rheumatology 2004; 16(3): 254–61 “Insufficient data are available to fully assess the risk of lymphoma and malignancies, although there is no strong evidence of increased risk.” Salliot & van der Heijde, Ann Rheum Dis 2009; 68: 1100–4 “Recent work suggests that it is the disease itself, not its treatment, that is associated with increased risk of lymphoma in patients with rheumatoid arthritis.” Kaiser, Clinical Lymphoma Myeloma 2008; 8(2): 87–93

Four emerging concepts in CD  Objective evidence of the presence of inflammation should drive clinical decision making, not the presence of symptoms in isolation  The pharmacokinetics of TNFα-inhibitors are complex and therapy should be optimized for individual patients  Combining antimetabolite therapy and a TNFα-inhibitor results in optimal efficacy and protects the latter against sensitization  Step-care is obsolete (CD vs UC?)